Differential Splicing Alters Subcellular Localization of the Alpha but not Beta Isoform of the MIER1 Transcriptional Regulator in Breast Cancer Cells by Clements, Jaclyn A. et al.
Differential Splicing Alters Subcellular Localization of the
Alpha but not Beta Isoform of the MIER1 Transcriptional
Regulator in Breast Cancer Cells
Jaclyn A. Clements
¤, F. Corinne Mercer, Gary D. Paterno, Laura L. Gillespie*
Terry Fox Cancer Research Laboratories, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada
Abstract
MIER1 was originally identified in a screen for novel fibroblast growth factor activated early response genes. The mier1 gene
gives rise to multiple transcripts encoding protein isoforms that differ in their amino (N-) and carboxy (C-) termini. Much of
the work to date has focused on the two C-terminal variants, MIER1a and b, both of which have been shown to function as
transcriptional repressors. Our previous work revealed a dramatic shift in MIER1a subcellular localization from nuclear in
normal breast tissue to cytoplasmic in invasive breast carcinoma, suggesting that loss of nuclear MIER1a may play a role in
breast cancer development. In the present study, we investigated whether alternative splicing to include a cassette exon
and produce an N–terminal variant of MIER1a affects its subcellular localization in MCF7 breast carcinoma cells. We
demonstrate that this cassette exon, exon 3A, encodes a consensus leucine-rich nuclear export signal (NES). Inclusion of this
exon in MIER1a to produce the MIER1-3Aa isoform altered its subcellular distribution in MCF7 cells from 81% nuclear to 2%
nuclear and this change in localization was abrogated by mutation of critical leucines within the NES. Treatment with
leptomycin B (LMB), an inhibitor of the nuclear export receptor CRM1, resulted in a significant increase in the percentage of
cells with nuclear MIER1-3Aa, from 4% to 53%, demonstrating that cytoplasmic localization of this isoform was due to
CRM1-dependent nuclear export. Inclusion of exon 3A in MIER1b to produce the N-terminal variant MIER1-3Ab however had
little effect on the nuclear targeting of this isoform. Our results demonstrate that alternative splicing to include exon 3A
specifically affects the localization pattern of the a isoform.
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Introduction
MIER1 is a fibroblast growth factor (FGF)-activated transcrip-
tional regulator [1] that is highly conserved in evolution, with 95%
identity between human [2,3] and mouse sequences [4] at the
amino acid level. The mier1 gene produces multiple distinct
transcripts through exon skipping, facultative intron usage,
alternative polyadenylation sites and the use of two alternate
promoters, P1 and P2 [3]. The resulting MIER1 proteins share a
common internal region, but vary in their amino (N-) and carboxy
(C-) terminal sequences. To date, we have cloned and character-
ized isoforms with three distinct N- and two distinct C- termini in
humans [3], although additional variants have been reported in
GenBank.
The N-terminal isoforms result from differential promoter usage
and alternative splicing [3] (Fig. 1A). Transcription from P1 or P2
produces mRNAs with distinct 59UTRs, but the resulting protein
sequences (named N2 and N3 in GenBank) are identical except for
the first two amino acids after the start methionine. A third N–
terminal isoform arises only during transcription from the P1
promoter, which allows for alternate inclusion of a cassette exon,
exon 3A; doing so produces a variant containing additional
sequence at its N-terminus (named N1 in GenBank). The two C-
termini differ significantly in size and sequence [3]: the a C-
terminus contains 23 residues and arises by removal of a
facultative intron during RNA processing, while the b isoform
contains 102 residues and results from inclusion of this intron with
subsequent read-through translation to a stop codon within the
intron.
All of the experimental research to date has focused on the
MIER1a and b C-terminal isoforms that lack the cassette exon 3A
sequence at their N-terminus. While no specific function has been
assigned to the b C-terminus yet, it contains a strong nuclear
localization signal (NLS) [3,5]. An additional weak, cryptic NLS
has been identified in the internal common region of MIER1,
however only the b C-terminal NLS was shown to be necessary
and sufficient to target MIER1 exclusively to the nucleus [5]. One
would therefore predict that MIER1b is nuclear, while MIER1a is
localized exclusively in the cytoplasm. However, we have
demonstrated that MIER1b is sometimes retained in the
cytoplasm, e.g. during early Xenopus development [6] and that
MIER1a isoform is occasionally targeted to the nucleus, e.g. in
human mammary ductal epithelial cells [7] and some cell lines
(unpublished observations). Thus, the NLS-dependent nuclear/
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32499cytoplasmic distribution of MIER1 is not absolute, but can vary
with cell type and stage of differentiation.
The common internal region of MIER1 contains several
domains important for its role in regulating transcription [1,8–
10]. These include an N-terminal acidic region, which can
function in isolation as a transcriptional activator [1]; an ELM2
[11] domain and a SANT [12] domain. ELM2 and SANT
domains have been found in a number of transcriptional co-
repressors, including NCoR [13], SMRT [14] and members of
the MTA family [15]. In MIER1, the ELM2 domain has been
shown to recruit histone deacetylase 1 (HDAC1) and repress
transcription [8]; the SANT domain interacts with Sp1,
displacing it from its cognate binding sites in the promoter of
regulated genes, including MIER1’s own promoter, and inter-
fering with transcription [9]. In addition, MIER1 has been shown
to bind CREB-binding protein (CBP) and inhibit its histone
acetyltransferase (HAT) activity [10]; the CBP interaction
domain has been mapped to the N–terminal region that includes
both acidic and ELM2 domains [10]. MIER1 also interacts with
the G9a histone methyltransferase [16], however its effect on the
activity of this chromatin modifying enzyme has yet to be
determined.
The MIER1a-specific sequence contains a classic LXXLL motif
[17] for interaction with nuclear hormone receptors. Indeed, we
have shown that MIER1a interacts with ERa in MCF7 cells and
that regulated overexpression inhibits estrogen-stimulated anchor-
age-independent growth [7]. Furthermore, analysis of the
MIER1a expression pattern in breast samples from patients
revealed a dramatic shift in the subcellular localization in ductal
epithelial cells, from nuclear to cytoplasmic, during progression to
invasive carcinoma [7]. These data suggest that controlling
nuclear levels of MIER1a may play an important role in the
development of invasive breast carcinoma.
Further examination of the sequence encoded by the cassette
exon 3A reveals the presence of a putative nuclear export signal
(NES) and therefore, alternative splicing has the potential to
regulate the subcellular localization of MIER1a. In this report, we
have investigated the ability of the exon 3A sequence to function in
nuclear export and have determined its effect on the subcellular
localization of the MIER1a and b isoforms.
Results and Discussion
Verification of the MIER1-3A initiation codon
In our original report describing the cloning and characteriza-
tion of human MIER1, the N–terminal variants were given the
non-descript names N1, N2 and N3 [3]. For clarity and ease of
understanding, we have renamed the variant containing exon 3A,
MIER1-3A; the name MIER1 refers to variants lacking exon 3A.
The cDNAs used in this study are the coding sequences of mier1a
Figure 1. Sequence encoded by exon 3A. (A) Schematic illustrating the 59end of the mier1 gene and the nucleotide & predicted amino acid
sequences of exon 3A. The upper diagram shows the location of exon 3A relative to the 2 promoters, P1& P2. The lower diagram shows the sequence
of exon 3A and illustrates alternative splicing to generate either mier1 (exons 2A+4; protein sequence (i)) or mier1-3A (exons 2A+3A+4; protein
sequence (ii)). The MIER1 start codon, located at the end of exon 2A, is highlighted yellow, as is a downstream in-frame ‘atg’. For the analysis in (B),
both highlighted ATGs were mutated to avoid the possibility of spurious translation initiation at the second ‘atg’; this double mutation changes the
putative protein sequence from MLKM to QLKL. The predicted start methionine for MIER1-3A is highlighted in blue; the consensus NES is underlined
and the hydrophobic residues are highlighted in green. For the analysis in (B), both the initiation and third codons were changed to produce an
MFMF-.IFIF mutant. (B) Effect of mutating the putative initiation codons on in vitro translation.
35S-labelled rabbit reticulocyte lysates programmed
with wild-type (lane 1) or either of the two mutant mier1-3A cDNAs (lanes 2–3) were immunoprecipitated with anti-MIER1 and analyzed by SDS-PAGE
and fluorography; the position of full–length MIER1-3A is indicated by an arrowhead and the molecular weight standards are shown on the left.
Mutation of the predicted initiation codon (MFMF-.IFIF) located within exon 3A abrogates production of full-length MIER1-3A (lane 2), while
mutation of upstream ATGs (MLKM-.QLKL) has no effect (lane 3), thus confirming the N-terminal sequence of this isoform. Note that full-length
MIER1 proteins migrate aberrantly on SDS-polyacrylamide gels, as has been reported for other proteins containing stretches of acidic residues [38,39].
doi:10.1371/journal.pone.0032499.g001
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3Aa (AY124186) and mier1-3Ab (AY124189).
Alternative splicing to include the cassette exon 3A positions the
additional sequence immediately after the second codon in
MIER1, located at the end of exon 2A (Fig. 1A). However, this
additional sequence shifts the reading frame such that the start of
translation for MIER1-3A is predicted to be in exon 3A (Fig. 1A,
‘M’ in blue box) and the alternate N-terminal sequence becomes:
MFMFNWFTDCLWTLFLSNYQ- (Fig. 1A).
To confirm the start of translation for this N-terminal isoform,
we produced two mutant constructs: in the first, the original
MIER1 initiation codon located at the end of exon 2A, as well as a
downstream in-frame ATG (Fig. 1A, yellow highlight), were
mutated, changing the encoded sequence from MLKM to QLKL.
In the second construct, the predicted initiation codon in exon 3A
and a downstream ATG that encodes the 3
rd residue were altered
to produce an MFMF-.IFIF mutant. Coupled in vitro transcrip-
tion-translation of the wild-type and mutant cDNAs was
performed followed by immunoprecipitation with an anti-MIER1
antibody and the resulting proteins analyzed by SDS-PAGE/
fluorography. As can be seen in Fig. 1B, mutating the ATGs in the
first construct did not prevent translation of full–length MIER1-3A
protein (compare lanes 1 and 3 in Fig. 1B), while mutating the
predicted initiation codon for MIER1-3A completely abolished
production of full-length protein (Fig. 1B, lane 2). These data
confirm that translation of the mier1-3A transcript is initiated
within exon 3A and encodes the N-terminal sequence:
MFMFNWFTDCLWTLFLSNYQ-.
Exon 3A encodes a classic leucine-rich nuclear export
signal
Analysis of the exon 3A amino acid sequence for possible motifs
revealed the presence of a putative leucine-rich NES (underlined
in Fig. 1A) that conforms to the consensus: w–x(2–3)–w–x(2–3)–w–x–
w, where w represents L, I, V, F or M and x is any amino acid
[18,19]. Our previous work demonstrated that the localization of
MIER1a changes from nuclear to cytoplasmic during progression
to invasive breast carcinoma [7]. Thus, the possibility that
alternative splicing could place a potential NES in the MIER1a
sequence has important implications for MIER1a’s role in breast
cancer. Therefore, we investigated the effect of including exon 3A
sequence on the subcellular localization of MIER1a, using MCF7
breast carcinoma cells. This cell line retains many of the
characteristics of differentiated epithelial cells (reviewed in [20])
and MIER1a is targeted to the nucleus in these cells (unpublished
observations).
MCF7 cells were transfected with plasmids encoding myc-
tagged MIER1a, myc-tagged MIER1-3Aa or myc-tag alone and
the localization of MIER1 was determined by immunocytochem-
istry. The anti-tag antibody (9E10) used for this study recognizes a
single protein band on a Western blot of transfected MCF7 cells
expressing MIER1a or MIER1-3Aa (Fig. 2A). Cells were scored
Figure 2. Subcellular localization of the MIER1a and MIER1-3Aa isoforms in MCF7 cells. MCF7 cells were transfected with myc-tagged
MIER1a, MIER1-3Aa or empty vector and analyzed by immunocytochemistry or immunoblotting with the 9E10 monoclonal antibody. (A) Western blot
of extracts from MCF7 cells transfected with empty vector (lane 1), myc-tagged mier1a (lane 2) or myc-tagged mier1-3Aa (lane 3); staining was
performed with the 9E10 antibody and confirms that a single protein in each cell extract is recognized by the antibody. The positions of the
molecular weight standards are indicated on the left. (B) Histogram showing the results of 3 experiments; random fields were selected and the
staining pattern of each cell within the field was scored visually according to the categories described in the Results & Discussion. 650–1,350 cells
were scored for each construct. Plotted is the percentage of cells in each category 6 S.D. (C) Illustrative examples of the observed staining pattern.
Panels (i) & (ii) show brightfield (BF) and the corresponding phase contrast (PhC) views of a staining control, prepared without primary antibody.
Panel (iii) shows cells expressing the myc-tag alone; examples of whole cell staining are indicated by arrowheads. Panels (iv) & (v) show cells
expressing MIER1-3Aa & MIER1a, respectively; note the absence of nuclear staining in panel (iv) while nuclei in panel (v) are intensely stained (arrows).
Scale bar=50 mm for (i)–(iii) and 25 mm for (iv)–(v).
doi:10.1371/journal.pone.0032499.g002
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nucleus was intensely stained, with little or no cytoplasmic
staining; CYTOPLASMIC: staining was observed throughout the
cytoplasm, with little or no staining in the nucleus; WHOLE CELL:
both the nucleus and cytoplasm were stained. Cells expressing the
myc-tag alone displayed primarily whole cell staining, in which the
nucleus and cytoplasm were stained with equal intensity (Fig. 2B &
2C, panel iii); this localization pattern was expected since the
molecular size of the expressed tag (8.5 kDa) is sufficiently small to
allow for passive diffusion between nucleus and cytoplasm [21]. In
cells expressing MIER1a, localization was nuclear in 81% of cells
(Fig. 2B and 2C, panel v); the remainder of the cells displayed
whole cell staining and for most of these, the nucleus was more
intensely stained than the cytoplasm. MIER1-3Aa expressing cells,
on the other hand, showed virtually no staining that was
exclusively nuclear (Fig. 2B). Instead, staining was cytoplasmic in
66% of cells and whole cell in 32% (Fig. 2B and 2C, panel iv), with
most of the latter category displaying equal intensity staining in the
nucleus and cytoplasm. These data demonstrate that addition of
the exon 3A sequence in MIER1a changes its subcellular
localization in MCF7 cells.
To determine whether the localization of MIER1-3Aa in the
cytoplasm is due to increased nuclear export rather than
inhibition of nuclear import, we examined the effect of
leptomycin B (LMB) on the localization pattern of MIER1a
and MIER1-3Aa proteins. LMB blocks nuclear export by
covalently modifying CRM1 [22,23], a key receptor in NES-
mediated nuclear export (reviewed in [24]), while having no effect
on import. Therefore, if the exon-3A sequence functions in
nuclear export, one would expect to see an accumulation of
MIER1-3Aa in the nucleus of treated cells. MCF7 cells
expressing MIER1a or MIER1-3Aa were treated with 5 ng/ml
LMB for 24 h and the localization pattern was determined by
confocal microscopy. In this and subsequent experiments, the
‘Whole Cell’ staining category was subdivided into two: 1) WHOLE
CELL N=C, in which the nucleus and cytoplasm were stained
with equal intensity, and 2) WHOLE CELL N.C, in which the
nucleus was much more intensely stained than the cytoplasm.
LMB had no effect on the subcellular localization pattern of
MIER1a (Fig. 3A). However, for MIER1-3A, the percentage of
cells with exclusively nuclear MIER1-3Aa increased from 4% to
53% in the presence of LMB (Fig. 3A). There was also a shift in
the pattern of whole cell staining: in the absence of LMB, the
majority of cells displayed equal intensity nuclear and cytoplasmic
staining, while the majority of LMB-treated cells in this category
showed more intense staining in the nucleus than in the
cytoplasm. These data demonstrate that the preferential cyto-
plasmic localization of MIER1-3Aa is due to CRM1-dependent
nuclear export.
To confirm that nuclear export of MIER1-3Aa is due to the
identified NES, we mutated the consensus sequence. Previous
studies have demonstrated that mutating the last 2 hydrophobic
residues in the consensus is sufficient to interfere with NES activity
[18,25]. Therefore, we produced a
14,16L-.A double mutant.
MCF7 cells expressing MIER1a, MIER1-3Aa or the NES mutant
were scored for subcellular localization by confocal microscopy.
Mutating the NES consensus resulted in a significant increase in
the percentage of cells with exclusively nuclear staining, from 4%
to 76%, with a concomitant decrease in the percentage of cells
showing whole cell N=C staining (Fig. 3B–C). Moreover, no
exclusively cytoplasmic staining was observed (Fig. 3C). These
results provide evidence that the identified NES functions in
nuclear export and is responsible for the cytoplasmic localization
of the MIER1-3Aa isoform.
Nuclear localization of MIER1b is not affected by the
inclusion of exon 3A sequence
MIER1b contains a strong nuclear localization signal (NLS) in
its b-specific C-terminus [5] and in most cells, it is targeted
exclusively to the nucleus [1,5]. Therefore, we investigated
whether the inclusion of exon 3A sequence would alter this
pattern. MCF7 cells expressing myc-tagged MIER1b, MIER1-
3Ab, MIER1a, MIER1-3Aa or myc-tag alone were analyzed by
confocal microscopy (Fig. 4). As expected, the expressed myc-tag
alone was distributed throughout the cell (Fig. 4A, panel a-c and
4B) and MIER1b was exclusively nuclear in all cells (Fig. 4A, panel
j-l and 4B). Likewise, MIER1a was predominantly nuclear
(Fig. 4A, panel d-f and 4B) and very few cells (,6%) expressing
MIER1-3Aa displayed nuclear staining (Fig. 4A, panel g–i and
4B). Interestingly, the MIER1-3Ab localization pattern did not
mirror that of MIER1-3Aa; instead, 80% of cells displayed
nuclear staining (Fig. 4A, panel m-o and Fig. 4B) and most of the
remaining 20% showed whole cell staining, with the nucleus more
intensely stained than the cytoplasm (Fig. 4B). Furthermore, none
of the cells expressing MIER1-3Ab showed exclusively cytoplas-
mic staining (Fig. 4B), as seen with MIER1-3Aa.
To further characterize the localization of the MIER1 isoforms,
we performed an analysis of the confocal z-stacks, using an Image J
software program to provide a quantitative measure of the
fluorescence in the nuclear and cytoplasmic compartments of
cells expressing each isoform. The results of this analysis (Fig. 4C)
show that for the 3 isoforms: MIER1a, MIER1b and MIER1-
3Ab, more than 80% of the protein is localized in the nucleus,
while for MIER1-3Aa, over 70% of the protein is cytoplasmic.
Taken together, our results demonstrate that exon 3A functions
specifically to shuttle the a isoform from the nucleus to the
cytoplasm.
The exon 3A sequence appears to function specifically to
regulate nuclear levels of MIER1a. There are numerous examples
of transcriptional regulators, whose function is altered in neoplastic
cells by changes in nucleo-cytoplasmic distribution. Classic
examples include Rb [26], p53 [27] and BRCA1 (reviewed in
[28]); the mechanisms responsible are diverse and involve
mutation, phosphorylation, monoubiquitylation and alternative
splicing (reviewed in [28,29]). The latter has been described as a
regulatory mechanism for the Kruppel-like zinc finger transcrip-
tion factor 6 (KLF6) [30,31]. KLF6 functions as a tumour
suppressor [32] but a splice variant, KLF6-SV1, truncated at its C-
terminus, localizes in the cytoplasm where it acts as a dominant
negative to antagonize KLF6 growth suppressive activity [30].
Increased expression of this alternatively spliced oncogenic isoform
has been described in a number of cancers, including prostate,
colorectal, pancreatic and ovarian (reviewed in [33]).
Our results suggest that controlling differential splicing to alter
nuclear levels of MIER1a could represent an important
mechanism for regulating its chromatin modifying activities and
ultimately gene expression; it might also play a role in the
development of invasive breast carcinoma. Given these results, it
will be important to examine the expression pattern of MIER1-
3Aa in breast tumour samples, once suitable antibodies become
available.
Materials and Methods
Cell culture
The MCF7 cell line was purchased from the American Tissue
Culture Collection and cultured in DMEM (GIBCO) containing
10% fetal calf serum (GIBCO) in a 37uC incubator with 5% CO2.
To inhibit nuclear export, 5 ng/ml leptomycin B (Sigma-Aldrich
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microscopy.
Plasmids and site-directed mutagenesis
The structure of the human mier1 gene, the sequence of its
transcripts and preparation of myc-tagged MIER1 constructs have
been described previously [3]. Primers for mutating the ATGs and
the putative NES were designed using Stratagene’s QuikChange
Primer Design program. Mutagenesis was carried out using
Stratagene’s QuikChange Lightning kit according to the manu-
facturer’s instructions and the following sets of primers: for
MLKM-.QLKL, forward and reverse primers were: 59-CAATG-
CAGACAAGACGGATGTGCAGCTGAAATTGTGCATCA-
GATGTTTATGTTT-39 and 59-AAACATAAACATCTGAT-
GCACAATTTCAGCTGCACATCCGTCTTGTCTGCATTG-
39 respectively. For MFMF-.IFIF, forward and reverse primers
were: 59-ATGCTGAAAATGTGCATCAGATCTTTATCTT-
TAATTGGTTTACAGACTGTC-39 and 59-GACAGTCTG-
TAAACCAATTAAAGATAAAGATCTGATGCACATTTTCA-
GCAT-39, respectively. For the NES mutant,
14,16LRA, forward
and reverse primers were: 59-GGTTTACAGACTGTCTGTG-
GACTGCTTTCGCGTCAAATTACCAGCCATCTGTTG-39
and 59-CAACAGATGGCTGGTAATTTGACGCGAAAGCA-
GTCCACAGACAGTCTGTAAACC-39, respectively. Myc-
tagged MIER1-3A constructs were produced by PCR cloning
full-length sequences into the BglII site of the CS3+MT plasmid as
described in [3], using the forward primer: 59-CGGGATCCA-
GATGTTTATGTTTAATTGGTTTACA-39 and either 59-
CGGGATCCAAAACAAGACCACAGAAGC-39 (alpha) or 59-
CTTGAAAACACAGATGACTAAGGATCCCG-39 (beta) re-
verse primers. All plasmids were prepared using Clontech’s
NucleoBond Endotoxin-free Maxi Plasmid kit and the sequenc-
es/mutations were confirmed by automated dideoxynucleotide
sequencing of both strands (performed by The Centre for Applied
Genomics, The Hospital for Sick Children, Toronto, Canada).
In vitro coupled transcription/translation,
immunoprecipitation and Western Blotting
35S-labelled MIER1 was synthesized using a coupled in vitro
transcription/translation system (Promega Corp.) and subjected to
immunoprecipitation, as previously described [34], with the
following modifications: 2 ml of translation products were
immunoprecipitated using 10 ml of an anti-MIER1 antibody [3]
that recognizes a sequence in the common internal region;
immunoprecipitated proteins were analyzed by SDS-PAGE
followed by fluorography as in [34].
Western blot analysis was performed as in [34], using 60 mg
cellular protein per lane. Transfers were performed onto Hybond-
P PVDF membranes (GE Healthcare Corp.); the membranes were
stained using a 1:1000 dilution of 9E10 monoclonal antibody,
1:3000 HRP-labelled sheep anti-mouse antibody and Amersham’s
ECL Western Blotting System (GE Healthcare Corp.).
Transient Transfection
Cells were transfected according to the manufacturers’ protocol
using either the Mirus TransIT-LT1 transfection reagent (Med-
icorp, Inc.) and a 3:1 ratio of reagent:DNA (v/w), or by
electroporation using the Neon system (Invitrogen Corp.) and
the following parameters: 1250 V, 20 ms, 2 pulses. Eighteen hours
prior to transfection with the TransIT-LT1 reagent, cells were
plated at a density of 2610
4/well into Falcon 8-well culture slides
(BD BioSciences) and all transfections were performed using
0.26 mg of plasmid. For electroporation, 3610
5 cells and 0.5 mgo f
plasmid were loaded into a 10 ml tip; after transfection, cells were
dispensed at a density of 2610
4/well into 8-well culture slides for
immunocytochemistry (ICC)/confocal or at a density of 3610
5 in
35 mm dishes for Western blot (WB) analysis. Transfected cells
were cultured for 48 h, then either fixed in 4% paraformalde-
hyde/PBS (ICC) or solubilized in 500 ml SDS-PAGE sample
buffer (WB).
Immunocytochemistry, Confocal Microscopy and Image
Analysis
After fixation, cells were processed for either immunocyto-
chemistry (ICC) as described previously [35] or for confocal
microscopy as described in [36], using the 9E10 anti-myc
monoclonal antibody, prepared as in [10] and used at a 1:200
dilution. Cells were incubated with primary antibody overnight at
4uC. For ICC, cells were incubated with a 1:200 dilution of HRP-
labelled sheep anti-mouse antibody (GE Healthcare Corp.) for 1 h
and stained using SigmaFast 3,39-Diaminobenzidine (DAB)
(Sigma-Aldrich Co.), prepared according to the manufacturer’s
instructions. For confocal analysis, a DyLight-488 labeled donkey
anti-mouse secondary antibody (Jackson ImmunoResearch Labo-
ratories, Inc.) was utilized; the antibody was re-constituted
according to the manufacturer’s instructions and used at a 1:250
dilution. Nuclei were counterstained using 2.5 mg/ml 49,6-
diamidino-2-phenylindole (DAPI; Sigma-Aldrich Co.). All slides
were mounted in 10% glycerol/PBS. Brightfield and phase
contrast images were captured using an Olympus BH-2 micro-
scope equipped with a CoolSnap digital camera. Fluorescence
images were acquired using sequential Z-stage scanning in two
channels (DAPI and DyLight488) on an Olympus FluoView
FV1000 confocal microscope; Z-stacks were compiled into
individual images.
Quantitative analysis of confocal z-stacks was performed using
Image J software v1.46 [37] as follows: using random fields, cell
outlines from the projected z-stacks were traced, the sum of the
pixel values within the outlines in the MIER1 channel was
determined and the background was subtracted; this value was
used to represent MIER1 fluorescence within the whole cell. The
nuclei were outlined and the sum of the pixel values was obtained
and the background subtracted; this value was used as MIER1
fluorescence within the nucleus. The nuclear value was subtracted
from the whole cell value to obtain that representing MIER1
Figure 3. Function of exon 3A sequence in nuclear export. (A) Effect of leptomycin B on localization of MIER1a and MIER1-3Aa. Cells were
transfected, treated with 5 ng/ml LMB for 24 h and analyzed by confocal microscopy, using DAPI, 9E10 and a DyLight-488 secondary antibody .
Histogram showing the results of 2 experiments; the staining pattern from random fields was scored visually according to the categories described in
the Results & Discussion. Plotted is the percentage of cells in each category 6 S.D; 75–90 cells were scored for each construct with each treatment.
Note the increase in nuclear localization in treated cells expressing MIER1-3Aa. (B) and (C) Mutation of the NES consensus increases nuclear
localization. MCF7 cells were transfected with plasmids encoding myc-tagged MIER1a, MIER1-3Aa or MIER1-3Aa containing a double mutation in the
NES consensus (NES mutant) and analyzed by confocal microscopy using the antibodies described in (A). (B) Illustrative examples of cells expressing
MIER1a (a–c), MIER1-3Aa (d–f) or the NES mutant (g–i); arrowheads indicate nuclei. (C) Histogram showing the results of 2 experiments; the staining
pattern was scored as in (A). Plotted is the percentage of cells in each category 6 S.D; 85–130 cells were scored for each construct.
doi:10.1371/journal.pone.0032499.g003
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were measured from 4 independent experiments.
Acknowledgments
JAC was the recipient of a Memorial University of Newfoundland Dean’s
Fellowship.
Author Contributions
Conceived and designed the experiments: LLG GDP. Performed the
experiments: JAC FCM LLG. Analyzed the data: JAC FCM GDP LLG.
Contributed reagents/materials/analysis tools: GDP LLG. Wrote the
paper: LLG JAC FCM GDP.
References
1. Paterno GD, Li Y, Luchman HA, Ryan PJ, Gillespie LL (1997) cDNA cloning of
a novel, developmentally regulated immediate early gene activated by fibroblast
growth factor and encoding a nuclear protein. J Biol Chem 272: 25591–25595.
2. Paterno GD, Mercer FC, Chayter JJ, Yang X, Robb JD, et al. (1998) Molecular
cloning of human er1 cDNA and its differential expression in breast tumours and
tumour-derived cell lines. Gene 222: 77–82.
3. Paterno GD, Ding Z, Lew YY, Nash GW, Mercer FC, et al. (2002) Genomic
organization of the human mi-er1 gene and characterization of alternatively
spliced isoforms: regulated use of a facultative intron determines subcellular
localization. Gene 295: 79–88.
4. Thorne LB, Grant AL, Paterno GD, Gillespie LL (2005) Cloning and
characterization of the mouse ortholog of mi-er1. DNA Seq 16: 237–240.
5. Post JN, Gillespie LL, Paterno GD (2001) Nuclear localization signals in the
Xenopus FGF embryonic early response 1 protein. FEBS Lett 502: 41–45.
6. Luchman HA, Paterno GD, Kao KR, Gillespie LL (1999) Differential nuclear
localization of ER1 protein during embryonic development in Xenopus laevis.
Mech Dev 80: 111–114.
7. McCarthy PL, Mercer FC, Savicky MW, Carter BA, Paterno GD, et al. (2008)
Changes in subcellular localisation of MI-ER1 alpha, a novel oestrogen receptor-
alpha interacting protein, is associated with breast cancer progression.
Br J Cancer 99: 639–646.
8. Ding Z, Gillespie LL, Paterno GD (2003) Human MI-ER1 alpha and beta
function as transcriptional repressors by recruitment of histone deacetylase 1 to
their conserved ELM2 domain. Mol Cell Biol 23: 250–258.
9. Ding Z, Gillespie LL, Mercer FC, Paterno GD (2004) The SANT domain of
human MI-ER1 interacts with Sp1 to interfere with GC box recognition and
repress transcription from its own promoter. J Biol Chem 279: 28009–28016.
10. Blackmore TM, Mercer CF, Paterno GD, Gillespie LL (2008) The transcrip-
tional cofactor MIER1-beta negatively regulates histone acetyltransferase
activity of the CREB-binding protein. BMC Research Notes 1: 68.
11. Solari F, Bateman A, Ahringer J (1999) The Caenorhabditis elegans genes egl-27
and egr-1 are similar to MTA1, a member of a chromatin regulatory complex,
and are redundantly required for embryonic patterning. Development 126:
2483–2494.
12. Aasland R, Stewart AF, Gibson T (1996) The SANT domain: a putative DNA-
binding domain in the SWI-SNF and ADA complexes, the transcriptional co-
repressor N-CoR and TFIIIB. Trends Biochem Sci 21: 87–88.
13. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, et al. (1995) Ligand-
independent repression by the thyroid hormone receptor mediated by a nuclear
receptor co-repressor. Nature 377: 397–404.
14. Chen JD, Evans RM (1995) A transcriptional co-repressor that interacts with
nuclear hormone receptors. Nature 377: 454–457.
15. Kumar R, Wang RA, Bagheri-Yarmand R (2003) Emerging roles of MTA
family members in human cancers. Semin Oncol 30: 30–37.
16. Wang L, Charroux B, Kerridge S, Tsai CC (2008) Atrophin recruits HDAC1/2
and G9a to modify histone H3K9 and to determine cell fates. EMBO Rep 9:
555–562.
17. Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in
transcriptional co-activators mediates binding to nuclear receptors. Nature 387:
733–736.
18. la Cour T, Kiemer L, Molgaard A, Gupta R, Skriver K, et al. (2004) Analysis
and prediction of leucine-rich nuclear export signals. Protein Engineering
Design and Selection 17: 527–536.
19. Kosugi S, Hasebe M, Tomita M, Yanagawa H (2008) Nuclear export signal
consensus sequences defined using a localization-based yeast selection system.
Traffic 9: 2053–2062.
20. Lacroix M, Leclercq G (2004) Relevance of Breast Cancer Cell Lines as Models
for Breast Tumours: An Update. Breast Cancer Research and Treatment 83:
249–289.
21. Marfori M, Mynott A, Ellis JJ, Mehdi AM, Saunders NF, et al. (2011) Molecular
basis for specificity of nuclear import and prediction of nuclear localization.
Biochimica et biophysica acta 1813: 1562–1577.
22. Wolff B, Sanglier J-J, Wang Y (1997) Leptomycin B is an inhibitor of nuclear
export: inhibition of nucleo-cytoplasmic translocation of the human immuno-
deficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA.
Chemistry & biology 4: 139–147.
23. Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y, et al. (1998)
Leptomycin B Inhibition of Signal-Mediated Nuclear Export by Direct Binding
to CRM1. Experimental Cell Research 242: 540–547.
24. Cook A, Bono F, Jinek M, Conti E (2007) Structural Biology of Nucleocyto-
plasmic Transport. Annual Review of Biochemistry 76: 647–671.
25. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, et al. (1999) A
leucine-rich nuclear export signal in the p53 tetramerization domain: regulation
of subcellular localization and p53 activity by NES masking. Embo J 18:
1660–1672.
26. Jiao W, Datta J, Lin H-M, Dundr M, Rane SG (2006) Nucleocytoplasmic
Shuttling of the Retinoblastoma Tumor Suppressor Protein via Cdk Phosphor-
ylation-dependent Nuclear Export. Journal of Biological Chemistry 281:
38098–38108.
27. Carter S, Bischof O, Dejean A, Vousden KH (2007) C-terminal modifications
regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol 9:
428–435.
28. Fabbro M, Henderson BR (2003) Regulation of tumor suppressors by nuclear-
cytoplasmic shuttling. Experimental Cell Research 282: 59–69.
29. Salmena L, Pandolfi PP (2007) Changing venues for tumour suppression:
balancing destruction and localization by monoubiquitylation. Nat Rev Cancer
7: 409–413.
30. Narla G, DiFeo A, Reeves HL, Schaid DJ, Hirshfeld J, et al. (2005) A Germline
DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor
Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. Cancer
Research 65: 1213–1222.
31. Rodriguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA (2010)
Nucleo-cytoplasmic localization domains regulate Kruppel-like factor 6 (KLF6)
protein stability and tumor suppressor function. PLoS One 5.
32. Narla G, Heath KE, Reeves HL, Li D, Giono LE, et al. (2001) KLF6, a
Candidate Tumor Suppressor Gene Mutated in Prostate Cancer. Science 294:
2563–2566.
33. DiFeo A, Martignetti JA, Narla G (2009) The role of KLF6 and its splice
variants in cancer therapy. Drug resistance updates : reviews and commentaries
in antimicrobial and anticancer chemotherapy 12: 1–7.
34. Ryan PJ, Gillespie LL (1994) Phosphorylation of phospholipase C gamma 1 and
its association with the FGF receptor is developmentally regulated and occurs
during mesoderm induction in Xenopus laevis. Dev Biol 166: 101–111.
35. Reynolds JN, Prasad A, Gillespie LL, Paterno GD (1996) Developmental
expression of functional GABAA receptors containing the gamma 2 subunit in
neurons derived from embryonal carcinoma (P19) cells. Brain Res Mol Brain
Res 35: 11–18.
36. Williams KL, Mearow KM (2011) Phosphorylation status of heat shock protein
27 influences neurite growth in adult dorsal root ganglion sensory neurons in
vitro. J Neurosci Res 89: 1160–1172.
37. Rasband WS (1997–2011) U.S. National Institutes of Health, Bethesda,
Maryland, USA Image J website. Available: http://imagej.nih.gov/ij/. Accessed
2012 Feb 1.
38. Armstrong DJ, Roman A (1993) The anomalous electrophoretic behavior of the
human papillomavirus type 16 E7 protein is due to the high content of acidic
amino acid residues. Biochem Biophys Res Commun 192: 1380–1387.
39. Iakoucheva LM, Kimzey AL, Masselon CD, Smith RD, Dunker AK, et al.
(2001) Aberrant mobility phenomena of the DNA repair protein XPA. Protein
Sci 10: 1353–1362.
Figure 4. Subcellular localization of the MIER1-3Ab isoform in MCF7. MCF7 cells were transfected with myc-tagged MIER1a, MIER1-3Aa,
MIER1b, MIER1-3Ab or empty vector and analyzed by confocal microscopy, performed as in the legend to Fig. 3. (A) Illustrative examples of cells
expressing myc-tag alone (a–c), MIER1a (d–f), MIER1-3Aa (g–i), MIER1b (j–l) or MIER1-3Ab (m–o). Arrowheads indicate nuclei and the arrow indicates
staining in the cytoplasm. (B) Histogram showing the results of 4 independent experiments; the staining pattern was scored as in the legend to Fig. 3.
Plotted is the percentage of cells in each category 6 S.D; 55–160 cells were scored for each construct. Note that, unlike MIER1-3Aa, MIER1-3Ab
remains predominantly nuclear. (C) Bar graph showing the intracellular distribution of each construct. Pixel values for the nuclear and in the
cytoplasmic areas were measured using Image J v1.46 and plotted as a proportion of the total signal. Shown is the proportion in each compartment,
using measurements from 30–40 cells for each construct.
doi:10.1371/journal.pone.0032499.g004
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